Evommune Q3 net loss more than doubles to $30.88 million
EVMN•Evommune’s third-quarter 2026 net loss more than doubled year over year to $30.88 million, with no revenue generated. It reported $262.3 million in cash, cash equivalents and investments at September 30, and expects its cash runway to extend into the second half of 2029.
1. Quarterly results
Evommune reported a third-quarter 2026 net loss of $30.88 million, more than double the year-earlier loss. The company generated no revenue, while research and development expenses rose 25% year over year to $24.55 million.
2. Cash and clinical plans
Cash, cash equivalents and investments totaled $262.3 million at September 30, with cash runway expected into the second half of 2029. Evommune licensed EVO570 for $30 million upfront and expects its Phase 1 trial to begin in the first quarter of 2027. A Phase 2b atopic dermatitis trial of EVO301 is expected to start in mid-2027.
